Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Colorectal
Descriptor: Poor Prognosis

Reference Number: 480
Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, Paty PB, Weiser MR. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 248, 219-28 (2007)
PubMed link      E-mail link

Reference Number: 485
Inoue Y, Miki C, Watanabe H, Ojima E, Kusunoki M. Genomic instability and tissue expression of angiogenic growth factors in sporadic colorectal cancer. Surgery. 139, 305-11 (2006)
PubMed link      E-mail link

Reference Number: 734
Miki C, Inoue Y, Hiro J, Ojima E, Araki T, Uchida K, Kusunoki M. Combined measurement of hepatocyte growth factor and carcinoembryonic antigen as a prognostic marker for patients with dukes a and B colorectal cancer: results of a five-year study. Dis Colon Rectum. 49, 1710-8 (2006)
PubMed link      E-mail link

Reference Number: 837
Osada S, Matsui S, Komori S, Yamada J, Sanada Y, Ihawa A, Tanaka Y, Tokuyama Y, Okumura N, Nonaka K, Hosono Y, Takahashi T, Yamaguchi K, Yoshida K. Effect of hepatocyte growth factor on progression of liver metastasis in colorectal cancer. Hepatogastroenterology. 57, 76-80 (2010)
PubMed link      E-mail link

Reference Number: 1056
Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, Strippoli A, Ferrara AM, Bagalà C, Cassano A, Larocca LM, Barone C. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer. 10, 325-32 (2011)
PubMed link      E-mail link

Reference Number: 1157
Liu Y, Li Q, Zhu L. Expression of the hepatocyte growth factor and c-Met in colon cancer: correlation with clinicopathological features and overall survival. Tumori. 98, 105-12 (2012)
PubMed link      E-mail link

Reference Number: 1328
Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis. 28, 9-18 (2013)
PubMed link      E-mail link

Reference Number: 1434
Samamé Pérez-Vargas JC1, Biondani P, Maggi C, Gariboldi M, Gloghini A, Inno A, Volpi CC, Gualeni AV, di Bartolomeo M, de Braud F, Castano A, Bossi I, Pietrantonio F. Role of cMET in the development and progression of colorectal cancer. Int J Mol Sci. 14, 18056-77 (2013)
PubMed link      E-mail link

Reference Number: 1436
Bendell JC1, Ervin TJ, Gallinson D, Singh J, Wallace JA, Saleh MN, Vallone M, Phan SC, Hack SP. Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. Clin Colorectal Cancer. 12, 218-22 (2013)
PubMed link      E-mail link

Reference Number: 1447
Takahashi N1, Yamada Y1, Furuta K2, Honma Y1, Iwasa S1, Takashima A1, Kato K1, Hamaguchi T1, Shimada Y1. Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer. Br J Cancer. 110, 2716-27 (2014)
PubMed link      E-mail link

Reference Number: 1656
Lee J, Jain A, Kim P, Lee T, Kuller A, Princen F, In-GuDo, Kim SH, Park JO, Park YS, Singh S, Kim HC. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status. PLoS One. 9, e103551 (2014)
PubMed link      E-mail link

Reference Number: 1832
Seo AN, Park KU, Choe G, Kim WH, Kim DW, Kang SB, Lee HS. Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients. Tumour Biol. 36, 9813-21 (2015)
PubMed link      E-mail link

Reference Number: 1859
Liu Y, Yu XF, Zou J, Luo ZH. Prognostic value of c-Met in colorectal cancer: a meta-analysis. World J Gastroenterol. 21, 3706-10 (2015)
PubMed link      E-mail link